Friday, October 28, 2016

Spersatear




Spersatear may be available in the countries listed below.


Ingredient matches for Spersatear



Hypromellose

Hypromellose is reported as an ingredient of Spersatear in the following countries:


  • South Africa

International Drug Name Search


Posted by at No comments:
Labels:

Dapson PCH




Dapson PCH may be available in the countries listed below.


Ingredient matches for Dapson PCH



Dapsone

Dapsone is reported as an ingredient of Dapson PCH in the following countries:


  • Netherlands

International Drug Name Search


Posted by at No comments:
Labels:

Nor-Q. D




Ingredient matches for Nor-Q.D.



Norethisterone

Norethisterone is reported as an ingredient of Nor-Q.D. in the following countries:


  • United States

International Drug Name Search


Posted by at No comments:
Labels:

Juvenile Rheumatoid Arthritis Medications


Definition of Juvenile Rheumatoid Arthritis: A chronic, inflammatory disease that may cause joint or connective tissue damage. The onset occurs before age 16.

Drugs associated with Juvenile Rheumatoid Arthritis

The following drugs and medications are in some way related to, or used in the treatment of Juvenile Rheumatoid Arthritis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under Juvenile Rheumatoid Arthritis

  • Juvenile Idiopathic Arthritis (5 drugs)

  • Still's Disease (2 drugs)

Learn more about Juvenile Rheumatoid Arthritis

Medical Encyclopedia:

  • Juvenile rheumatoid arthritis




Drug List:


Posted by at No comments:
Labels:

Thursday, October 27, 2016

Copaxone


Copaxone is a brand name of glatiramer, approved by the FDA in the following formulation(s):


COPAXONE (glatiramer acetate - injectable; subcutaneous)



  • Manufacturer: TEVA

    Approval date: February 12, 2002

    Strength(s): 20MG/ML [RLD]

Has a generic version of Copaxone been approved?


No. There is currently no therapeutically equivalent version of Copaxone available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Copaxone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Copolymer-1 improvements in compositions of copolymers
    Patent 5,981,589
    Issued: November 9, 1999
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014




  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,054,430
    Issued: April 25, 2000
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014




  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,342,476
    Issued: January 29, 2002
    Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
    Assignee(s): Yeda Research & Development Company Limited
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014
      ✓ 
      Patent use: METHOD OF TREATING MS BY ADMINISTERING COPAXONE




  • Copolymer-1 improvements on compositions of copolymers
    Patent 6,362,161
    Issued: March 26, 2002
    Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
    Assignee(s): Yeda Research & Development Company Limited
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014
      ✓ 
      Patent use: METHOD OF TREATING MS BY ADMINISTERING COPAXONE




  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,620,847
    Issued: September 16, 2003
    Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014
      ✓ 
      Drug substance




  • Copolymer-1 improvements in compositions of copolymers
    Patent 6,939,539
    Issued: September 6, 2005
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research & Development
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014
      ✓ 
      Drug substance




  • Copolymer-1 improvements in compositions of copolymers
    Patent 7,199,098
    Issued: April 3, 2007
    Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
    Assignee(s): Yeda Research and Development Co., Ltd.
    The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
    Patent expiration dates:

    • May 24, 2014
      ✓ 
      Drug substance



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • February 27, 2012 - INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS

See also...

  • Copaxone Consumer Information (Drugs.com)
  • Copaxone Consumer Information (Wolters Kluwer)
  • Copaxone injection Consumer Information (Cerner Multum)
  • Copaxone Advanced Consumer Information (Micromedex)
  • Copaxone AHFS DI Monographs (ASHP)
  • Glatiramer Consumer Information (Wolters Kluwer)
  • Glatiramer injection Consumer Information (Cerner Multum)
  • Glatiramer Subcutaneous Advanced Consumer Information (Micromedex)
  • Glatiramer Acetate AHFS DI Monographs (ASHP)

Posted by at No comments:
Labels:

Nifedipine PCH




Nifedipine PCH may be available in the countries listed below.


Ingredient matches for Nifedipine PCH



Nifedipine

Nifedipine is reported as an ingredient of Nifedipine PCH in the following countries:


  • Netherlands

International Drug Name Search


Posted by at No comments:
Labels:

Somatulina Autogel




Somatulina Autogel may be available in the countries listed below.


Ingredient matches for Somatulina Autogel



Lanreotide

Lanreotide acetate (a derivative of Lanreotide) is reported as an ingredient of Somatulina Autogel in the following countries:


  • Portugal

  • Spain

International Drug Name Search


Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)